Table 2.
TLR2 (with TLR1 or TLR6) targeting ligands in clinical trials
| Ligand | Phase | Application | Target TLR adjuvant/drug | Sponsor/collaborators | NCT number | Type | Purpose |
|---|---|---|---|---|---|---|---|
| CBLB612 | Phase 2 | Breast cancer | TLR2 agonist/drug | Cleveland BioLabs, Inc | NCT02778763 | Synthetic lipopeptide | Neutropenia/recover blood cells count |
| SV‐283 (NY‐ESO‐1) | Phase 1 | Cancer | TLR2 agonist/adjuvant | SapVax LLC | NA | Combination of peptide and SM | Immune stimulation |
| ISA‐201 | Phase 2 | Head and neck tumor | TLR2/1 agonist/adjuvant | ISA Pharmaceuticals BV | NCT02821494 | Combination of peptide and SM, peptide | DC maturation |
| OPN‐305‐110 | Phases 1 and 2 | Second‐line and first line lower risk myelodysplastic syndrome | TLR2 antagonist/drug | Opsona Therapeutics Ltd | NCT03337451 | Monoclonal antibody | Anti‐inflammation |
| OPN‐305 | Phase 2 | Myelodysplastic syndrome, inflammatory disease, pancreas tumor, kidney transplant rejection | TLR2 antagonist/drug | Opsona Therapeutics Ltd | NCT02363491 | Monoclonal antibody | Anti‐inflammation |
Abbreviations: DC, dendritic cells; NA, not available; NCT, national clinical trial; SM, small molecule; TLR, Toll‐like receptor.